Blog

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.

The history of Hua Medicine

Headquartered in Shanghai, China, and founded by CEO and executive director Li Chen in 2011, Hua Medicine focuses on innovative and potentially disease-modifying therapeutics for T2D based on glucose homeostasis research. The company’s phase 3 monotherapy (SEED) and remission (DREAM) studies of its flagship drug, dorzagliatin, suggest that it could change the treatment paradigm by restoring the body’s ability to sense and regulate blood glucose levels, as well as preventing the ongoing loss of β-cell function.

Supported by international blue-chip investors, including ARCH Venture Partners, Venrock, Fidelity Investments and WuXi AppTec, Hua Medicine’s leadership team includes world-class scientists and industry veterans. The main goal of the company is to advance the treatment of T2D by addressing the root cause of the disease, rather than targeting high blood-sugar levels, a well-recognized primary symptom of the disease.